Our team - including David Kang, Michael Travanty, Trevor Knight, Scott Beacher, and Kevin Swanson - will be at PDA - Parenteral Drug Association's PDA Universe next week! Drop by booth 18 to say hello and explore our portfolio of auto-injectors, including our High-Volume Auto-Injector (HVAI™) — designed to enable subcutaneous delivery of large-volume biologics. See you in Vienna! #HVAI #Subcutaneous #PDAuniverse
Halozyme, Inc.
Biotechnology Research
San Diego, California 21,519 followers
At Halozyme we continuously push the pace of innovation.
About us
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the company's partners make progress developing and commercializing their products being developed with ENHANZE®. We are a diverse team, who are committed to bringing therapies and results to patients. It's not enough to be qualified and experienced at what you do, we are looking for people who believe in our mission and match our values. We are building a company where people can pursue their career goals in a supportive and collaborative team environment. Visit www.halozyme.com/careers for more details. We are Halozyme.
- Website
-
http://www.halozyme.com
External link for Halozyme, Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Specialties
- biotechnology, hyaluronidase, rHuPH20, and subcutaneous biologics
Locations
-
Primary
Get directions
12390 El Camino Real
San Diego, California 92130, US
-
Get directions
12500 Whitewater Dr
Minnetonka, Minnesota 55343, US
-
Get directions
100 Princeton South Corporate Center
300
Ewing, New Jersey 08628, US
Employees at Halozyme, Inc.
-
Louise Brandy
-
Amit Paz
Build, transform, grow, deliver. Supporting the delivery of innovative therapies to patients with value-oriented supply chain management.
-
Richa Krishnanand
Customer-Centric Technology & Product Leader | Driving Digital Transformation and Growth using Data & AI
-
Joy Breed
Experienced, result-oriented technology executive, focused on Healthcare Informatics. Management of complex IT solutions, PMO, Dev teams, Tech Ops &…
Updates
-
One week countdown to PDA Universe! We’re counting down to the PDA Universe of Pre-Filled Syringes and Injection Devices Conference, happening October 21–22 in Vienna, Austria — and we’re excited to be part of it! Visit us at Booth 18 Our team will be on-site and would love to connect! Stop by to explore our portfolio of auto-injectors, including our High-Volume Auto-Injector (HVAI™) — designed to enable subcutaneous delivery of large-volume biologics. Scientific Contributions We’re proud to be sharing our latest innovations through two posters and one presentation: Posters Preclinical Evaluation on the Functionality and Usability of a High-Volume Auto-Injector (HVAI) as an Off-Body Injector Enabled by Recombinant Human Hyaluronidase PH20 (rHuPH20) Guided Poster Walk Part I Tuesday October 21, 2025 10:40-11:25 Preclinical Investigation of Subcutaneous Delivery of an Antibody-Drug Conjugate (ADC) with Recombinant Human Hyaluronidase PH20 (rHuPH20) and a High-Volume Auto-Injector Guided Poster Walk Part II Tuesday October 21, 2025 15:40-16:25 Tech Talk Presentation Development of a High-Volume Auto-Injector (HVAI) Tech Talks Wednesday, October 22 14:00–14:10 Want to meet at the show? Drop us a comment — we’d love to connect!
-
-
Reminder: Dr. Charles Theuer at Fierce Biotech Week – Wednesday! We’re in Boston for Fierce Biotech Week, and we’re proud to have our Chief Medical Officer, Dr. Charles Theuer, featured in a key panel discussion: Panel: “Formulation, Product and Process Innovation Enabling Next-Gen Therapies” Wednesday, October 8 2:45–3:30 PM Room: Cezanne Join us as Dr. Theuer shares insights on how innovation in formulation and process design is unlocking the potential of next-generation therapies. If you’re attending, we’d love to connect and talk about how subcutaneous drug delivery technologies are shaping the future of medicine. #FierceBiotechWeek #Biotech #Pharma #DrugDelivery #Innovation #Leadership #Halozyme
-
-
Today at Fierce Biotech Week in Boston Dr. Helen Torley, CEO & President, will be speaking in a fireside chat with Nandini Kashyap: “The Future, Under Your Skin – Why Subcutaneous Technology is the Next Frontier in Medicine” 1:30 - 2 PM | Tuesday, October 7 She’ll explore how subcutaneous drug delivery is reshaping the biotech landscape and what it means for the future of medicine. If you’re attending Fierce Biotech, this is a session worth adding to your schedule. https://ow.ly/zj2g50X7nON #FierceBiotechWeek #Biotech #Pharma #DrugDelivery #Innovation #Leadership #Halozyme
-
-
We’re heading to Boston for Fierce Biotech Week! We’re looking forward to connecting with industry leaders and exploring the future of biotech innovation—and we’re proud to have two of our leaders featured in key sessions: Dr. Helen Torley, CEO & President Fireside Chat: “The Future, Under Your Skin – Why Subcutaneous Technology is the Next Frontier in Medicine” Tuesday, October 7 | 1:30–2 PM Dr. Charles Theuer, Chief Medical Officer Panel Discussion: “Formulation, Product and Process Innovation Enabling Next-Gen Therapies” Wednesday, October 8 | 2:45–3:30 PM We’re excited to share how our subcutaneous drug delivery technologies are shaping the future of medicine. If you’ll be in Boston, we’d love to connect! #FierceBiotechWeek #Biotech #Pharma #DrugDelivery #Innovation #Leadership #Halozyme
-
-
Our announcement this morning to acquire Elektrofi represents an exciting opportunity to extend Halozyme’s vision and breadth of innovative technologies for subcutaneous drug delivery, setting new standards of convenience, accessibility and treatment options. We look forward to welcoming Elektrofi’s talented team as we embark on our next chapter of drug delivery innovation to continue to drive value for all of our stakeholders including our partners, patients, and shareholders. To learn more about the acquisition, we invite you to read our press release here: https://ow.ly/s4Lr50X4Trx
-
-
We’re heading to Boston for Fierce Biotech Week! Join us October 7–9, 2025 as we connect with industry leaders to explore the future of biotech innovation. We’re proud to have two of our leaders featured in key sessions: Dr. Helen Torley, CEO & President Fireside Chat: “The Future, Under Your Skin – Why Subcutaneous Technology is the Next Frontier in Medicine” Tuesday, October 7 | 1:30–2 PM Dr. Charles Theuer, Chief Medical Officer Panel Discussion: “Formulation, Product and Process Innovation Enabling Next-Gen Therapies” Wednesday, October 8 | 2:45–3:30 PM We’re excited to share how our subcutaneous drug delivery technologies are shaping the future of medicine. Hope to see you there! #FierceBiotech #BiotechInnovation #SubcutaneousDelivery #DrugDelivery #Halozyme #LeadershipInBiotech
-
-
We kicked off our annual fundraiser for St. Jude Children's Research Hospital with an awesome picnic — an afternoon filled with sunshine, One Team spirit, and shared purpose. Over the past two years, our team has proudly raised more than $100,000 for St. Jude Children’s Research Hospital. This year, we’re stepping up — literally — with a bold goal: 25 million steps taken collectively by our team $25,000 raised to support St. Jude’s lifesaving mission We’re honored to once again partner with an organization that ensures families never receive a bill for treatment, travel, housing, or food — because all a family should worry about is helping their child live. Follow along as we walk, run, roll, and rally together as One Team in support of this incredible cause. #StJude #Fundraiser #OneTeam #CorporateGiving #GiveBack #HopeLivesHere
-
-
Halozyme’s Tania Thomas and Ryan Nolan, alongside peers from the Subcutaneous Drug Development & Delivery Consortium, have contributed to a newly published article in the Journal of Controlled Release : "An industry perspective on clinical development and regulatory strategies for subcutaneously administered high-dose biologics" Published: August 21, 2025 Journal: Journal of Controlled Release (Elsevier) This collaborative work outlines key considerations and approaches for advancing high-dose biologics via the subcutaneous route, reflecting shared industry experiences and regulatory insights. Read the article here: https://ow.ly/oI2G50WXM7I #DrugDelivery #Biologics #SubcutaneousDelivery #Pharma #RegulatoryStrategy #ClinicalDevelopment #Halozyme
-
-
Tram Bui, our VP of Corporate Communications and Investor Relations, will host 1x1 investor meetings tomorrow tomorrow at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. Date: Tuesday, September 9, 2025 Location: New York, NY Format: 1x1 Meetings Looking forward to engaging with the investment community and sharing our latest updates! #InvestorRelations #CorporateCommunications #HCWainwright #IRMeetings #NYCConference
-